Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature

References

• Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012 Jan 5;119(1):34–43.
   PubMed Web of Science ®Google Scholar
• Guru Murthy GS, Pondaiah SK, Abedin S, et al. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. Leuk Lymphoma. 2019 May;60(5):1171–1178. DOI:https://doi.org/10.1080/10428194.2018.1522442.
   PubMed Web of Science ®Google Scholar
• Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017 Mar 2;129(9):1134–1142.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006 Jul 15;108(2):465–472.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Thomas D, Cortes J, et al. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010 May 15;116(10):2290–2300.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th. Lyon: IARC; 2017.
   Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995 Oct;9(10):1783–1786.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009 Feb;10(2):147–156. DOI:https://doi.org/10.1016/S1470-2045(08)70314-0.
   PubMed Web of Science ®Google Scholar
• Jain N, Lamb AV, O’Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14;127(15):1863–1869.
   PubMed Web of Science ®Google Scholar
• Cordo V, van der Zwet JCG, Cante-Barrett K, et al., T-cell Acute Lymphoblastic Leukemia: a Roadmap to Targeted Therapies. Blood Cancer Discov. 2021 Jan;2(1): 19–31. doi:https://doi.org/10.1158/2643-3230.BCD-20-0093.
   PubMedGoogle Scholar
• Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006 Jan 15;107(2):473–479.
   PubMed Web of Science ®Google Scholar
• Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014 Aug;166(3):421–424. DOI:https://doi.org/10.1111/bjh.12882.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qian JJ, Zhou YL, et al. Comparison of early T-cell precursor and non-ETP subtypes among 122 Chinese adults with acute lymphoblastic leukemia. Front Oncol. 2020;10:1423.
   PubMed Web of Science ®Google Scholar
• Kroeze E, Loeffen JLC, Poort VM, et al. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Adv. 2020 Jul 28;4(14):3466–3473.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Gokbuget N. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma. 2009;9(3):S214–21.
   PubMedGoogle Scholar
• Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009 Dec 10;114(25):5136–5145.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):580–588.
   PubMedGoogle Scholar
• Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011 Aug 25;118(8):2077–2084.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012 Aug 30;120(9):1868–1876.
   PubMed Web of Science ®Google Scholar
• Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014 Jun 12;123(24):3739–3749.
   PubMed Web of Science ®Google Scholar
• Genesca E, Morgades M, Gonzalez-Gil C, et al. Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leuk Res. 2021 Jun 8;109:106612. DOI:https://doi.org/10.1016/j.leukres.2021.106612.
   PubMed Web of Science ®Google Scholar
• Kim R, Boissel N, Touzart A, et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia. 2020 Jul;34(7):1730–1740. DOI:https://doi.org/10.1038/s41375-019-0685-4.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009 Jan;46(1):64–75.
   PubMed Web of Science ®Google Scholar
• Kota VK, Hathaway AR, Shah BD, et al. Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma Blood. 2015;126(23): Abstract 3762.
   Google Scholar
• Kozlowski P, Astrom M, Ahlberg L, et al. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden. Eur J Haematol. 2014;92(5):377–381. DOI:https://doi.org/10.1111/ejh.12269.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003 Mar 1;21(5):774–780. DOI:https://doi.org/10.1200/JCO.2003.02.053.
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 1;112(5):1646–1654.
   PubMed Web of Science ®Google Scholar
• Testi AM, Canichella M, Vitale A, et al. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. Am J Hematol. 2021 Mar 1;96(3):292–301.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar;29(3):526–534. DOI:https://doi.org/10.1038/leu.2014.229.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Arnold R, et al. Successful subtype oriented treatment strategies in adult T-all; results of 744 patients treated in three consecutive GMALL studies. Blood. 2009;114(22):324. Abstract 324. DOI:https://doi.org/10.1182/blood.V114.22.324.324.
   Web of Science ®Google Scholar
• Goekbuget N, Baumann A, and Beck J, et al. PEG-asparaginase intensification in adult Acute Lymphoblastic Leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) study 07/2003. Blood. 2010;116(21): Abstract 494.
   Web of Science ®Google Scholar
• Muffly L, Curran E. Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit? Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):17–23.
   PubMedGoogle Scholar
• Meyer LK, Huang BJ, Delgado-Martin C, et al. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 Feb 3;130(2):863–876.
   PubMed Web of Science ®Google Scholar
• Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19(4):269–275. DOI:https://doi.org/10.1002/mpo.2950190411.
   PubMedGoogle Scholar
• Moricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016 Apr 28;127(17):2101–2112.
   PubMed Web of Science ®Google Scholar
• Teuffel O, Kuster SP, Hunger SP, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011 Aug;25(8):1232–1238. DOI:https://doi.org/10.1038/leu.2011.84.
   PubMed Web of Science ®Google Scholar
• McNeer JL, Nachman JB. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol. 2010 Jun;149(5):638–652.
   PubMed Web of Science ®Google Scholar
• Lopes AM, Oliveira-Nascimento L, Ribeiro A, et al. Therapeutic l-asparaginase: upstream, downstream and beyond. Crit Rev Biotechnol. 2017 Feb;37(1):82–99. DOI:https://doi.org/10.3109/07388551.2015.1120705.
   PubMed Web of Science ®Google Scholar
• Lanvers-Kaminsky C, Niemann A, Eveslage M, et al. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Leuk Lymphoma. 2020 Jan;61(1):138–145. DOI:https://doi.org/10.1080/10428194.2019.1658099.
   PubMed Web of Science ®Google Scholar
• Heo YA, Syed YY, Keam SJ. Pegaspargase: a Review in Acute Lymphoblastic Leukaemia. Drugs. 2019 May;79(7):767–777. DOI:https://doi.org/10.1007/s40265-019-01120-1.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson K, and Neuberg DS, et al. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial. Blood. 2015;126(23): Abstract 80.
   Web of Science ®Google Scholar
• Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020 Mar 26;135(13):987–995.
   PubMed Web of Science ®Google Scholar
• Advani AS, Larsen E, Laumann K, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 Jan 26;5(2):504–512.
   PubMed Web of Science ®Google Scholar
• Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009 Jun;146(1):76–85. DOI:https://doi.org/10.1111/j.1365-2141.2009.07712.x.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Baumann A, Beck J, et al. PEG-asparaginase intensification in adult Acute Lymphoblastic Leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) study 07/2003. Blood. 2009;116(1): Abstract 494.
   Google Scholar
• Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 Aug;91(8):819–823. DOI:https://doi.org/10.1002/ajh.24419.
   PubMed Web of Science ®Google Scholar
• Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children’s oncology group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926–2934.
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 Mar;32(3):606–615. DOI:https://doi.org/10.1038/leu.2017.265.
   PubMed Web of Science ®Google Scholar
• Huguet F, Chevret S, Leguay T, et al. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: report of the Randomized GRAALL-2005 Clinical Trial. J Clin Oncol. 2018 Aug 20;36(24):2514–2523.
   PubMed Web of Science ®Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 Apr 4;133(14):1548–1559.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Morgades M, Montesinos P, et al. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: results of the ALLRE08 PETHEMA trial. Cancer Med. 2020 Apr;9(7):2317–2329. DOI:https://doi.org/10.1002/cam4.2814.
   PubMed Web of Science ®Google Scholar
• Raj TA, Smith AM, Moore AS. Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. Int J Nanomedicine. 2013;8:4361–4369.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005 Nov;80(11):1517–1527.
   PubMed Web of Science ®Google Scholar
• Cordova-Serrano RD, Almanza-Huante E, Fernandez-Sanchez E, et al. Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry. Leuk Lymphoma. 2021;9:1–7.
   Google Scholar
• Larson RA. Managing CNS disease in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018 Jan;59(1):3–13.
   PubMed Web of Science ®Google Scholar
• Jeha S, Pei D, Choi J, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16. J Clin Oncol. 2019 Dec 10;37(35):3377–3391.
   PubMed Web of Science ®Google Scholar
• Dunsmore KP, Winter SS, Devidas M, et al. Children’s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282–3293.
   PubMed Web of Science ®Google Scholar
• Vora A, Andreano A, Pui CH, et al. Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy. J Clin Oncol. 2016 Mar 20;34(9):919–926.
   PubMed Web of Science ®Google Scholar
• Kelly MJ, Trikalinos TA, Dahabreh IJ, et al. Cranial radiation for pediatric T-lineage acute lymphoblastic leukemia: a systematic review and meta-analysis. Am J Hematol. 2014 Oct;89(10):992–997. DOI:https://doi.org/10.1002/ajh.23784.
   PubMed Web of Science ®Google Scholar
• Sancho JM, Ribera JM, Oriol A, et al. Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis. Blood. 2005; 10611: Abstract 1841. doi:https://doi.org/10.1182/blood.V106.11.1841.1841.
   Google Scholar
• Su W, Thompson M, Sheu RD, et al. Low-dose cranial boost in high-risk adult acute lymphoblastic leukemia patients undergoing bone marrow transplant. Pract Radiat Oncol. 2017 Mar - Apr;7(2):103–108. DOI:https://doi.org/10.1016/j.prro.2016.06.008.
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Yahalom J, Specht L, et al. Radiation in central nervous system leukemia: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):53–58.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007 Feb 1;109(3):944–950.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012 Sep 6;120(10):2032–2041.
   PubMed Web of Science ®Google Scholar
• Frey NV, Luger SM. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2015 Jul 30;126(5):589–596.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20;31(6):676–683.
   PubMed Web of Science ®Google Scholar
• Qian JJ, Hu X, Wang Y, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: a retrospective, multicenter, cohort study. Cancer Med. 2020 Aug;9(15):5327–5334. DOI:https://doi.org/10.1002/cam4.3079.
   PubMed Web of Science ®Google Scholar
• Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol. 2005 May 20;23(15):3376–3382. DOI:https://doi.org/10.1200/JCO.2005.03.426.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136–5142. DOI:https://doi.org/10.1182/blood-2006-11-056754.
   PubMed Web of Science ®Google Scholar
• Rodriguez CO Jr., Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003 Sep 1;102(5):1842–1848.
   PubMed Web of Science ®Google Scholar
• Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol. 2010 Dec 1;4:133–141. DOI:https://doi.org/10.4137/CMO.S4364.
   PubMedGoogle Scholar
• Gokbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011 Sep 29;118(13):3504–3511.
   PubMed Web of Science ®Google Scholar
• Candoni A, Lazzarotto D, Ferrara F, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020 Dec;95(12):1466–1472. DOI:https://doi.org/10.1002/ajh.25957.
   PubMed Web of Science ®Google Scholar
• Abaza Y, Mk H, Faderl S, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 Jan;93(1):91–99. DOI:https://doi.org/10.1002/ajh.24947.
   PubMed Web of Science ®Google Scholar
• Rowntree CJ, Kirkwood AA, Clifton-Hadley L, et al. First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK/09/006. Blood. 2021; 138Supplement 1: Abstract 366. doi:https://doi.org/10.1182/blood-2021-152355.
   Google Scholar
• Goekbuget N, Stelljes M, Viardot A, et al. First results of the risk-adapted, MRD-Stratified GMALL Trial 08/2013 in 705 adults with newly diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL. Blood. 2021; 138Supplement 1: Abstract 362. doi:https://doi.org/10.1182/blood-2021-146306.
   Google Scholar
• Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005 May 20;23(15):3396–3403.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. Am J Hematol. 2019 Feb;94(2):257–265. DOI:https://doi.org/10.1002/ajh.25338.
   PubMed Web of Science ®Google Scholar
• Raff T, Gokbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007 Feb 1;109(3):910–915.
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006 Feb 1;107(3):1116–1123.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017 Jul 13;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou Y, Huang X, et al. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia. Br J Haematol. 2021 Jun;193(6):1096–1104. DOI:https://doi.org/10.1111/bjh.17424.
   PubMed Web of Science ®Google Scholar
• Muffly L, Sundaram V, Chen C, et al. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv. 2021 Aug 24;5(16):3147–3151.
   PubMed Web of Science ®Google Scholar
• Bakr M, Rasheed W, Mohamed SY, et al. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012 Dec;18(12):1897–1904. DOI:https://doi.org/10.1016/j.bbmt.2012.07.011.
   PubMed Web of Science ®Google Scholar
• Hamilton BK, Rybicki L, Abounader D, et al. Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2017 Jul;23(7):1117–1121. DOI:https://doi.org/10.1016/j.bbmt.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Brammer JE, Saliba RM, Jorgensen JL, et al. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017 Jan;52(1):20–27. DOI:https://doi.org/10.1038/bmt.2016.194.
   PubMed Web of Science ®Google Scholar
• Aladag E, Aktimur SH, Aydin O, et al. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Munster Chemotherapy in Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):147–153. DOI:https://doi.org/10.1016/j.clml.2020.12.014.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010 Nov 25;116(22):4439–4443.
   PubMed Web of Science ®Google Scholar
• Marks DI, Wang T, Perez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010 Jul 22;116(3):366–374.
   PubMed Web of Science ®Google Scholar
• Samon JB, Castillo-Martin M, Hadler M, et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2012 Jul;11(7):1565–1575. DOI:https://doi.org/10.1158/1535-7163.MCT-11-0938.
   PubMed Web of Science ®Google Scholar
• Wei P, Walls M, Qiu M, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010 Jun;9(6):1618–1628. DOI:https://doi.org/10.1158/1535-7163.MCT-10-0034.
   PubMed Web of Science ®Google Scholar
• Staal FJ, Langerak AW. Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. Haematologica. 2008 Apr;93(4):493–497.
   PubMed Web of Science ®Google Scholar
• Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, et al. Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2006–2011.
   PubMed Web of Science ®Google Scholar
• Habets RA, de Bock CE, Serneels L, et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci Transl Med. 2019 May 29;11(494). DOI:https://doi.org/10.1126/scitranslmed.aau6246.
   Google Scholar
• Mroczek A, Zawitkowska J, Kowalczyk J, et al. Comprehensive Overview of Gene Rearrangements in Childhood T-Cell Acute Lymphoblastic Leukaemia. Int J Mol Sci. 2021 Jan 15;22(2):808.
   Web of Science ®Google Scholar
• Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015 Mar 12;125(11):1759–1767.
   PubMed Web of Science ®Google Scholar
• Verbeke D, Gielen O, Jacobs K, et al. Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia. Hemasphere. 2019 Dec;3(6):e310. DOI:https://doi.org/10.1097/HS9.0000000000000310.
   PubMed Web of Science ®Google Scholar
• Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738–3747.
   PubMed Web of Science ®Google Scholar
• Farhadfar N, Li Y, May WS, et al. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):246–251. DOI:https://doi.org/10.1016/j.hemonc.2019.10.002.
   PubMedGoogle Scholar
• McEwan A, Pitiyarachchi O, Viiala N. Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant. Hemasphere. 2020 Jun;4(3):e379.
   PubMed Web of Science ®Google Scholar
• La Starza R, Cambo B, Pierini A, et al. Venetoclax and bortezomib in relapsed/refractory early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. 2019;3.
   Web of Science ®Google Scholar
• Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 Mar 1;131(9):995–999.
   PubMed Web of Science ®Google Scholar
• Zheng W, Medeiros LJ, Young KH, et al. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014 Mar;55(3):624–627. DOI:https://doi.org/10.3109/10428194.2013.820293.
   PubMed Web of Science ®Google Scholar
• Bayon-Calderon F, Toribio ML, Gonzalez-Garcia S. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020 Oct 16;21(20):7685.
   PubMed Web of Science ®Google Scholar
• Touzart A, Boissel N, Belhocine M, et al. Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. Haematologica. 2020 Jun;105(6):1575–1581. DOI:https://doi.org/10.3324/haematol.2019.223677.
   PubMed Web of Science ®Google Scholar
• Mackowska N, Drobna-Sledzinska M, Witt M, et al. DNA Methylation in T-Cell Acute Lymphoblastic Leukemia: in Search for Clinical and Biological Meaning. Int J Mol Sci. 2021 Jan 30;22(3):1388.
   PubMed Web of Science ®Google Scholar
• Mamonkin M, Rouce RH, Tashiro H, et al. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20;126(8):983–992.
   PubMed Web of Science ®Google Scholar
• Gomes-Silva D, Srinivasan M, Sharma S, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 Jul 20;130(3):285–296.
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez D, Baroni ML, Gutierrez-Aguera F, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019 May 23;133(21):2291–2304.
   PubMed Web of Science ®Google Scholar